Business
Faron to Host BEXMAB Webcast
Faron to Host BEXMAB Webcast.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n\n \nFaron Pharmaceuticals Ltd.\n \n(\"Faron\" or the \"Company\")\n \n \nFaron to Host Webcast to Discuss Latest Data from Phase 1 Part of the BEXMAB Study of Bexmarilimab\n \nPress Release, March 14, 2024\n \nTURKU, Finland / BOSTON, Massachusetts - March 14, 2024 - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces it will host a virtual BEXMAB update event on Tuesday, March 19 at 11.00 EET/9am GMT, following the most recent data cut-off and scheduled analysis.\n \nParticipants of the webcast will include Dr. Mika Kontro, MD, PhD, Associate Professor at the University of Helsinki and BEXMAB Principal Investigator; Dr. Maija Hollmen, PhD, Chief Scientific Officer at Faron, Dr Juho Jalkanen, MD, PhD, Chief Operating Officer at Faron and members of Faron's senior management team.\n \nDuring the event the Company will discuss latest data from the ongoing BEXMAB trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients, with a particular focus on the durability of remission and objective responses following treatment with bexmarilimab in combination with standard of care. This interactive event will also include an introduction to myeloid leukemia, insights into bexmarilimab's unique mode of action and the Company's latest understanding of the early and long-term efficacy of bexmarilimab treatment. Faron will also provide an update on bexmarilimab's future development pathway and business opportunity. Part of the discussion will be done in Finnish and summary in English.\n \nThere will be an opportunity to ask questions during the webcast. To register for the event visit: https://faron.videosync.fi/bexmab-study-update/ or contact the IR team for more information at [email protected].\n \n \nFor more information please contact:\n \nInvestor Contact\nLifeSci Advisors\nDaniel Ferry\nManaging Director\[email protected]\n+1 (617) 430-7576\n \nMedia Contact\nICR Consilium\nMary-Jane Elliott, David Daley, Lindsey Neville\nPhone: +44 (0)20 3709 5700\nE-mail: [email protected] \n \nCairn Fi...